All News
Filter News
Found 2,730 articles
-
Repare Therapeutics Announces US$82.5 Million Series B Financing
9/4/2019
Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced the completion of a US$82.5 million Series B financing.
-
Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer
9/4/2019
Beam Therapeutics announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer.
-
GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference
9/3/2019
Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.
-
University of California granted new U.S. CRISPR-Cas9 patent related to single-guide RNA
9/3/2019
University's 12th U.S. patent adds new compositions for CRISPR-Cas9 gene-editing technology to overall patent portfolio; expects to add five more patents in near future
-
Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts
8/29/2019
Inscripta, Inc., developer of the world’s first benchtop platform for scalable Digital Genome Engineering, today announced the appointment of Deanna Church, Ph.D., Simon Cawley, Ph.D., and Nandini Krishnamurthy, Ph.D., three leading experts in bioinformatics, software engineering, and computational biology.
-
EdiGENE Changes Name to Modalis Therapeutics
8/29/2019
EdiGENE Corporation announced that the company has changed its name to Modalis Therapeutics Corporation.
-
The Alliance for Regenerative Medicine, which calls itself an “international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector,” issued a bioethical framework for gene editing’s use in therapeutic applications.
-
The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing
8/27/2019
The Alliance for Regenerative Medicine released a Therapeutic Developers’ Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications.
-
Seqster Unveils All-Star Strategic Advisory Board
8/22/2019
Seqster, the award-winning SaaS based technology platform for enabling consumer-centered health data management, today announced it appointed 9 strategic advisory board members to reinforce the company's mission to empower organizations to optimize the health of their employees, members or patients by providing the technology to effortlessly collect, own and share all of their health data on a nationwide basis.
-
University of California awarded new U.S. CRISPR-Cas9 patent - Aug. 20, 2019
8/20/2019
University continues momentum with sixth patent issued recently, 11th U.S. patent, expanding range of intellectual property related to the gene-editing technology
-
Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein
8/19/2019
Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Lawrence Klein, Ph.D., to its Board of Directors.
-
MilliporeSigma Granted 20 CRISPR Patents Total Worldwide
8/19/2019
MilliporeSigma, a leader in genome editing, today announced that the European, Israeli, South Korean and U.K. intellectual property offices have issued formal notices allowing MilliporeSigma's patent application claims covering CRISPR gene-editing technology, bringing the number of patents to 20 worldwide.
-
Milestone Pharmaceuticals Provides Positive Regulatory Updates for Etripamil Pivotal Program in PSVT and Reports Second Quarter 2019 Financial Results
8/13/2019
FDA agrees to allow initiation of NODE-303 open-label safety study without test dose and in population consistent with ongoing studies
-
KromaTiD Announces Closing of A Round Financing
8/13/2019
KromaTiD, Inc. announced today that it has successfully completed its A round of financing with Denver-based firm First Capital Ventures.
-
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
8/12/2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the second quarter ended June 30, 2019.
-
Under the terms of the acquisition, Bayer is buying the rest of the company for $240 million up front with an additional $360 million in various development milestones. This will correspond with the company’s value of about $1 billion.
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
8/8/2019
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.
-
Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics
8/8/2019
Another successful outcome from a Versant-created company in a breakthrough field
-
Pfizer's Rivipansel Fails to Meet Primary and Secondary Efficacy Endpoints in Sickle Cell Trial
8/5/2019
The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids. -
Vor Biopharma Appoints Dr. Bill Lundberg to Its Board of Directors
7/31/2019
Vor expands expert governance and oversight with highly regarded physician-scientist and R&D leader